Attention-deficit hyperactivity disorder (ADHD) is characterized by inattention, hyperactivity, and impulsivity.\[[@CR2]\] Globally, ADHD affects approximately 5--10% of children\[[@CR3]\] and persists into adolescence in up to 85% of affected individuals.\[[@CR4]\] Psychostimulants, such as methylphenidate and amfetamine, are the mainstay of treatment in ADHD.\[[@CR2]\]

A patch that delivers methylphenidate transdermally (methylphenidate transdermal system; Daytrana®) has been developed for the treatment of ADHD. The patch comprises a backing layer, an adhesive formulation that incorporates methylphenidate and uses DOT Matrix™ technology, and a protective liner, which is removed prior to application.\[[@CR5]\] The features and properties of methylphenidate transdermal system (including available patch sizes and the nominal methylphenidate dose delivered by each patch size) are shown in [table I](#Tab1){ref-type="fig"}. Once applied to the skin, methylphenidate transdermal system releases methylphenidate continuously. A potential advantage of this patch technology is that it allows the duration of the effect to be tailored to the individual by varying the duration of the application ('wear time').\[[@CR6]\]

![Features and properties of methylphenidate transdermal system (Daytrana®)\[[@CR1]\]](40268_2012_12030171_Tab1){#Tab1}

Methylphenidate transdermal system is approved in the US for the treatment of ADHD,\[[@CR5]\] and its use in children aged 6--12 years with ADHD has been reviewed previously.\[[@CR7]\] This profile report examines the use of methylphenidate transdermal system in adolescents aged 13--17 years with ADHD.

Adolescents aged 13--17 years with ADHD were randomized to receive methylphenidate transdermal system or placebo transdermal system in a double-blind, multicenter, 7-week trial (core trial).\[[@CR8]\] During a 5-week dose-optimization period, patients were titrated to their optimal methylphenidate transdermal system dosage (10, 15, 20, or 30 mg); the dose-optimization period was followed by a 2-week maintenance period, during which patients continued treatment at their optimal dosage. Patches were applied to the hip each morning and worn for 9 hours per day.\[[@CR8]\] Following the core trial, eligible patients could receive longer-term therapy with methylphenidate transdermal system 10--30 mg in a noncomparative extension study of ≈6 months duration.\[[@CR9]\]

According to the results of the core trial, methylphenidate transdermal system 10--30 mg was effective in adolescents aged 13--17 years with ADHD.\[[@CR8]\] The mean ADHD-Rating Scale-IV (ADHD-RS-IV) total score (primary endpoint) decreased to a significantly (p \< 0.001) greater extent in adolescents receiving methylphenidate transdermal system (n = 143) than in those receiving placebo transdermal system (n = 72), with a least squares mean between-group difference of -9.96 (95% CI -13.39, -6.53). The mean ADHD-RS-IV total score at study end was 17.7 in methylphenidate transdermal system recipients and 27.7 in placebo transdermal system recipients; the mean baseline scores were 36.4 and 36.6 in the corresponding treatment groups.\[[@CR8]\]

In the extension study, methylphenidate transdermal system recipients experienced a significant (p \< 0.001) reduction from the start of the core trial in the mean ADHD-RS-IV total score of 23.0.\[[@CR9]\]

Methylphenidate transdermal system was generally well tolerated in adolescents with ADHD. The vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial\[[@CR8]\] and the longer-term extension study.\[[@CR9]\] In the core trial, the most frequently reported treatment-emergent adverse events (occurring in ≥5% of methylphenidate transdermal system recipients and in numerically more methylphenidate transdermal system than placebo transdermal system recipients) included decreased appetite, irritability, upper respiratory tract infection, nausea, insomnia, dizziness, and decreased weight.\[[@CR8]\] A similar tolerability profile was seen during the extension study.\[[@CR9]\]

In the core trial, most of the skin reactions to methylphenidate transdermal system comprised mild erythema, and adherence of the methylphenidate transdermal system patch to the skin was rated at ≥90% overall.\[[@CR8]\] Changes in the blood pressure and pulse rate observed in the core\[[@CR8]\] and extension\[[@CR9]\] studies were typical of those seen in patients receiving stimulants.
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